Antidiabetic Pharmaceutical Raws Rosiglitazone CAS 122320-73-4 for
Product Name: Rosiglitazone
HCL;Rosiglitazone free base;Rosiglitazone and its
Rosiglitazone Usage And Synthesis
Description Rosiglitazone is a type of thiazolidinedione
antidiabetics. Thiazolidinedione are agonists for
peroxisome-proliferator–activated receptor γ (PPAR-γ). PPAR-γ
receptors are ligand-activated nuclear transcription factors that
modulate gene expression, lowering blood glucose primarily by
increasing insulin sensitivity in peripheral tissues.
Rosiglitazone is widely used to lower blood glucose levels in
patients with type 2 diabetes mellitus. Rosiglitazone
functionalizes by makes the cells of the body more sensitive to the
naturally produced insulin in body. It shouldn’t be used if the
patient is injecting or inhaling insulin. Using rosiglitazone with
insulin could increase the risk of heart failure. Patients having
heart failure with symptoms or moderate to severe heart failure
should not use Rosiglitazone.
Rosiglitazone Medical uses
Rosiglitazone was approved by the US FDA in 1999 and by the EMEA in
2000; the EMEA however required two postmarketing studies on
longterm adverse effects, one for chronic heart failure and the
other for cardiovascular effects. The drug was approved for
glycemic control in people with type 2 diabetes, as measured by
glycosylated haemoglobin A1c (HbA1c) as a surrogate endpoint,
similar to that of other oral antidiabetic drugs. The controversy
over adverse effects has dramatically reduced the use of
Rosiglitazone Side effects:
There was no difference in all cause and vascular death in a
meta-analysis of 4 trials against controls. Two meta-analyses of
cohort studies found excess deaths against pioglitazone.
An retrospective observational study performed using Medicare data
found that patients treated with rosiglitazone had a 27% higher
risk of stroke compared to those treated with pioglitazone.
GlaxoSmithKline reported a greater incidence of fractures of the
upper arms, hands and feet in female diabetics given rosiglitazone
compared with those given metformin or glyburide. The information
was based on data from the ADOPT trial The same increase has been
found with pioglitazone (Actos), another thiazolidinedione.
The risk of hypoglycaemia is reduced with thiazolidinediones when
compared with sulfonylureas; the risk is similar to the risk with
metformin (high strength of evidence).
Both thiazolidinediones cause a similar degree of weight gain to
that caused by sulfonylureas (moderate strength of evidence).
|DNP / Sodium 2,4-dinitrophenate|
|gamma-Butyrolactone / GBL|
|4-Acetamidophenol / Paracetamol|
|Tranexamic acid / Amstat|
|Lorcaserin hydrochloride hemihydrate|
|Triamcinolone acetonide acetate|
|Adrenosterone / 11-OXO|
|Apremilast (CC-10004) / Otezla|